ZYME Insider Trading Activity and SEC Form 4 Filings
ZYME insider trading summary
Over the past 12 months, insiders at Zymeworks Inc. (ZYME) reported 11 sales worth $5.0M by 5 insiders and no open-market purchases on SEC Form 4. Net insider selling was $5.0M.
Latest ZYME insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 9, 2026 | Adam Schayowitz | EVP, Head of R&D | Sell | $358K (13,832 @ $25.85) |
| Jan 12, 2026 | Jeffrey T L Smith | EVP & Chief Medical Officer | Sell | $211K (9,310 @ $22.67) |
| Jan 12, 2026 | Mark Hollywood | EVP & Chief Operating Officer | Sell | $139K (6,120 @ $22.67) |
| Jan 12, 2026 | Kenneth Galbraith | Chair & CEO | Sell | $690K (30,424 @ $22.67) |
| Jan 12, 2026 | Paul Andrew Moore | Chief Scientific Officer | Sell | $217K (9,560 @ $22.67) |
| Jan 5, 2026 | Paul Andrew Moore | Chief Scientific Officer | Sell | $233K (9,289 @ $25.10) |
| Jan 5, 2026 | Kenneth Galbraith | Chair & CEO | Sell | $569K (22,657 @ $25.10) |
| Jan 5, 2026 | Paul Andrew Moore | Chief Scientific Officer | Sell | $272K (10,821 @ $25.10) |
| Jan 5, 2026 | Kenneth Galbraith | Chair & CEO | Sell | $795K (31,686 @ $25.10) |
| Jan 5, 2026 | Jeffrey T L Smith | EVP & Chief Medical Officer | Sell | $264K (10,538 @ $25.10) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.